3-氨基-5,6-二甲基-吡嗪-2-羧酸 | 6294-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氨基-5,6-二甲基-吡嗪-2-羧酸
• 英文名称: 3-amino-5,6-dimethyl-pyrazine-2-carboxylic acid
• 英文别名: 3-Amino-5,6-dimethyl-pyrazin-2-carbonsaeure；2-Amino-5,6-dimethyl-pyrazin-carbonsaeure-(3)；2-Amino-3-carboxy-5,6-dimethyl-pyrazin；3-Amino-5,6-dimethylpyrazine-2-carboxylic acid
• CAS: 6294-71-9
• 化学式: C₇H₉N₃O₂
• mdl: MFCD00614348
• 分子量: 167.167
• InChiKey: PSXTUQVQRMXQNR-UHFFFAOYSA-N

物化性质

• 熔点：
  209-210 °C
• 沸点：
  379.6±42.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-氨基-5,6-二甲基-吡嗪-2-羧酸 在 二乙二醇单乙基醚醋酸酯 、 氨 、 水 、 溴 、 铜 作用下， 生成 5,6-二甲基-吡嗪-2,3-二胺
  参考文献：
  名称：

  吡嗪化学; 3-氨基-5，6-二甲基吡嗪酸的衍生物。

  摘要：

  DOI：

  10.1021/ja01183a117
• 作为产物：
  描述：

  6,7-二甲基蝶啶-2,4(1H,3H)-二酮 生成 3-氨基-5,6-二甲基-吡嗪-2-羧酸
  参考文献：
  名称：

  Some New Aminopyrazines and their Sulfanilamide Derivatives

  摘要：

  DOI：

  10.1021/ja01221a032

文献信息

• [EN] BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5<br/>[FR] AMIDES BIPYRIDYLES EN TANT QUE MODULATEURS DU RÉCEPTEUR-5 MÉTABOTROPIQUE DU GLUTAMATE
  申请人：MERCK & CO INC

  公开号：WO2005079802A1

  公开（公告）日：2005-09-01

  The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel amides and/or compositions containing these compounds.

  本发明涉及新型酰胺，如式(I)所示的酰胺：(I)，这些酰胺是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和症状，包括但不限于精神疾病和情绪障碍，如精神分裂症、焦虑、抑郁、双相障碍和恐慌，以及用于治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应，药物成瘾、药物滥用、药物戒断、肥胖和其他疾病。本发明还涉及包含这些化合物的药物组合物。本发明进一步提供了通过给予这些新型酰胺和/或含有这些化合物的组合物的有效量来治疗这些疾病和症状的方法。
• HETERO-FUSED CYCLIC COMPOUND
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US20160168176A1

  公开（公告）日：2016-06-16

  A compound represented by the formula (I) or a salt thereof: wherein a ring Z is a 5 to 6-membered heteroaromatic ring having one or two heteroatoms in the ring; X 1 is a hydrogen atom, a hydroxy group, a hydroxy C 1-6 alkyl group, —B(OH) 2 , a boronate ester group, a cyclic boronate ester group, a boranyl group, a cyclic boranyl group, —BF 3 M n1 , —Sn(R 12 )(R 13 )(R 14 ), a leaving group, a carboxy group, a formyl group, or —NR 16 R 17 ; and X 2 is a hydrogen atom or —CO 2 R 18 .

  一个由化学式(I)表示的化合物或其盐：其中环Z是一个具有一个或两个杂原子的5到6元杂芳香环；X1是氢原子、羟基、羟基C1-6烷基基团、—B(OH)2、硼酸酯基团、环硼酸酯基团、硼烷基团、环硼烷基团、—BF3Mn1、—Sn(R12)(R13)(R14)、一个离去基团、一个羧基、一个甲酰基，或—NR16R17；而X2是氢原子或—CO2R18。
• MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS
  申请人：Oertel Kai

  公开号：US20110229568A1

  公开（公告）日：2011-09-22

  Described herein are peptide derivatives and peptidomimetics as inhibitors for transglutaminases, methods for their preparation, pharmaceutical compositions containing said compounds as well as uses of said transglutaminase inhibitors in particular for the treatment of coeliac disease and transglutaminase dependent diseases.

  本文描述了肽衍生物和肽拟态物作为转麦芽胺酶的抑制剂，以及它们的制备方法、含有这些化合物的药物组合物，以及特别用于治疗乳糜热和依赖于转麦芽胺酶的疾病的转麦芽胺酶抑制剂的用途。
• MIF INHIBITORS AND THEIR USES
  申请人：Gaweco Anderson

  公开号：US20150065480A1

  公开（公告）日：2015-03-05

  The invention relates to MIF inhibitors; compositions comprising an effective amount of a MIF inhibitor; and methods for treating or preventing diseases associated with MIF.

  这项发明涉及MIF抑制剂；包含有效量MIF抑制剂的组合物；以及用于治疗或预防与MIF相关疾病的方法。
• Bipyridyl amides as modulators of metabotropic glutamate receptor-5
  申请人：Bonnefous Celine

  公开号：US20070149547A1

  公开（公告）日：2007-06-28

  The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel amides and/or compositions containing these compounds.

  本发明涉及新型酰胺，例如公式（I）所示的酰胺：（I），它们是mGluR5调节剂，可用于治疗或预防包括但不限于精神和情绪障碍（如精神分裂症、焦虑、抑郁、双相障碍和惊恐）以及疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍（如倒班工作引起的睡眠障碍和时差反应）、药物成瘾、药物滥用、药物戒断、肥胖症和其他疾病中涉及mGluR5的疾病和症状的治疗。本发明还涉及包含这些化合物的制药组合物。本发明还提供了通过给予这些新型酰胺和/或含有这些化合物的组合物的有效量来治疗这些疾病和症状的方法。